Posted by Michael Wonder on 26 Feb 2019
Lung cancer second treatment Alunbrig likely to get insurance coverage
25 February 2019 - The National Health Insurance Service’s drug price assessment committee recently evaluated Takeda’s Alunbrig (briganitib) as eligible for insurance benefit.
The medicine is a second-line treatment for anaplastic lymphoma kinase positive advanced non-small cell lung cancer, approved in Korea late last year.
If Takeda successfully proceeds with a drug pricing negotiation with the government, rival drugs such as Pfizer’s Xalkori (crizotinib), Novartis’ Zykadia (ceritinib), and Roche’s Alecensa (alectinib) will face different situations depending on their market share, industry watchers said.
